Edgewise Therapeutics, Inc. EWTX Enterprise value

Enterprise value at other companies

Bristol-Myers SquibbBMY

$152.27B+14.9%

Sarepta Therapeutics, Inc.SRPT

$1.52B-2.9%

CytokineticsCYTK

$11.71B+178%

PTC TherapeuticsPTCT

$5.2B+77.3%

Dyne Therapeutics, Inc.DYN

$2.41B+228%

Solid Biosciences Inc.SLDB

$844.27M+224%

FAQ

What is Edgewise Therapeutics, Inc.'s enterprise value?

Edgewise Therapeutics, Inc. (EWTX) reported enterprise value of $3.35B in Q1 2026.

How has Edgewise Therapeutics, Inc.'s enterprise value changed year-over-year?

Edgewise Therapeutics, Inc.'s enterprise value increased by 63.5% year-over-year, from $2.05B to $3.35B.

What is the long-term trend for Edgewise Therapeutics, Inc.'s enterprise value?

Over 3 years (2022 to 2025), Edgewise Therapeutics, Inc.'s enterprise value has grown at a 67.4% compound annual growth rate (CAGR), from $547.71M to $2.57B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.